4.2 Article

Renal Transport of Uric Acid: Evolving Concepts and Uncertainties

期刊

ADVANCES IN CHRONIC KIDNEY DISEASE
卷 19, 期 6, 页码 358-371

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ackd.2012.07.009

关键词

Urate; Hypouricemia; Hyperuricemia; URAT1; GLUT9

资金

  1. National Institutes of Health (NIH) [K01-DK090282, R01-DK091392, R01-DK041612, R21-CA152977]
  2. Takeda Pharmaceutical Company Ltd.
  3. Simmons Family Foundation
  4. UT Southwestern O'Brien Kidney Center [NIH P30-DK079328]

向作者/读者索取更多资源

In addition to its role as a metabolic waste product, uric acid has been proposed to be an important molecule with multiple functions in human physiologic and pathophysiologic processes and may be linked to human diseases beyond nephrolithiasis and gout. Uric acid homeostasis is determined by the balance between production, intestinal secretion, and renal excretion. The kidney is an important regulator of circulating uric acid levels by reabsorbing about 90% of filtered urate and being responsible for 60% to 70% of total body uric acid excretion. Defective renal handling of urate is a frequent pathophysiologic factor underpinning hyperuricemia and gout. Despite tremendous advances over the past decade, the molecular mechanisms of renal urate transport are still incompletely understood. Many transport proteins are candidate participants in urate handling, with URAT1 and GLUM being the best characterized to date. Understanding these transporters is increasingly important for the practicing clinician as new research unveils their physiologic characteristics, importance in drug action, and genetic association with uric acid levels in human populations. The future may see the introduction of new drugs that act specifically on individual renal urate transporters for the treatment of hyperuricemia and gout. (C) 2012 by the National Kidney Foundation, Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据